drugset / Trial / NCT02612623
An 8-Week Refractory Chronic Cough Study (MK-7264-021)
Phase 2
Completed
24 enrolled
Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This was an 8-week randomized, parallel, double-blind, placebo-controlled study of gefapixant (AF-219) in participants with refractory chronic cough.
Timeline
- Start
- 2015-12-17
- Primary completion
- 2016-05-04
- Completion
- 2016-05-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gefapixant | Small molecule | 15 mg | Oral |
| Subject | Gefapixant | Small molecule | 30 mg | Oral |
| Subject | Gefapixant | Small molecule | 50 mg | Oral |